Lv5
1110 积分 2022-08-16 加入
Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy
13天前
已完结
Comparison of different maintenance regimens following first-line immunochemotherapy for advanced non-small cell lung cancer
16天前
已关闭
Osimertinib combined with anlotinib as first-line treatment in advanced ormetastatic NSCLC patients with EGFR mutation: a prospective, single arm,exploratory study
27天前
已完结
Perioperative penpulimab-based combination therapy in patients with resectable non-small cell lung cancer (ALTERL043): an open-label, multicenter, randomized, phase II trial
1个月前
已完结
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer
1个月前
已完结
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial
3个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC
3个月前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
3个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer
4个月前
已完结
健康人CIK细胞输注对恶性肿瘤患者细胞免疫功能的影响
3个月前
已采纳
皖公网安备34019202002308
